Clinical Trial Update: Adjuvant Imatinib in High-risk Gastrointestinal Stromal Tumor (GIST) With C-kit Mutation [Phase 2]

View source ↗

Summary

Phase 2 trial updating adjuvant imatinib in high-risk gastrointestinal stromal tumor (GIST) with C-kit mutation; completed with results posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumors

Drugs mentioned

• Imatinib (imatinib)

Snippet

Sponsor: Asan Medical Center | Conditions: Sarcoma, Gastrointestinal Stromal Tumors | Phase 2 | Status: COMPLETED | Results posted: 2015-07-27